- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02596802
Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia (FETO)
December 4, 2023 updated by: Anthony Johnson
Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)
The goal is to assess the feasibility and safety of implementing Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy in fetuses with severe left Congenital Diaphragmatic Hernia (CDH) at UTHealth.
UTHealth's success in this study (with an initial 5 patients) will determine the feasibility of UTHealth's future participation in multi-center trials of this intervention.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anthony Johnson, DO
- Phone Number: 832 325-7288
- Email: Anthony.Johnson@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas health Science Center at Houston
-
Contact:
- Anthony Johnson, DO
- Phone Number: 832-325-7288
- Email: Anthony.Johnson@uth.tmc.edu
-
Contact:
- Percy Pacora Portella, MD, MPH
- Phone Number: 713-500-6421
- Email: Percy.N.PacoraPortella@uth.tmc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pregnant women age 18 years and older
- Singleton pregnancy
- Normal fetal karyotype with confirmation by culture results. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is > 26 weeks
- Isolated Left CDH with liver up
- O/E LHR < 30% - Gestation age at time of enrollment prior to 29 wks plus 5 days as determined by clinical information (LMP, 1st or 2nd trimester ultrasound) and evaluation of first ultrasound (measured at 270 to 296 weeks) at the time of surgery
- Gestational age at FETO procedure with O/E LHR < 30% at 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound
- Patient meets psychosocial criteria
- Informed consent
Exclusion Criteria:
- Patient < 18 years of age
- Multi-fetal pregnancy
- History of natural rubber latex allergy
- Preterm labor, cervix shortened (<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa
- Psychosocial ineligibility, precluding consent: Inability to reside within 30 minutes of The Fetal Center at Children's Memorial Hermann Hospital. and inability to comply with the travel for the follow-up requirements of the trial; Patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at The Fetal Center at Children's Memorial Hermann Hospital.
- Right sided CDH or bilateral CDH, isolated left sided with O/E LHR ≥25% (measured at 18 weeks 0 days to 29 weeks 5 days) as determined by ultrasound[1]
- Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. No cases will be removed post hoc if abnormalities are discovered in the course of post-operative monitoring
- Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy
- History of incompetent cervix with or without cerclage
- Placental abnormalities (previa, abruption, accrete) known at time of enrollment
- Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
- Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment
- Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality
- There is no safe or technically feasible fetoscopic approach to balloon placement
- Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FETO therapy
Intervention name: FETO therapy
|
Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Successful placement of Balt Goldbal2 balloon
Time Frame: 7 weeks after placement
|
7 weeks after placement
|
Successful removal of Balt Goldbal2 balloon
Time Frame: within 5 weeks prior to delivery
|
within 5 weeks prior to delivery
|
Gestational age at delivery
Time Frame: at delivery
|
at delivery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lung volume
Time Frame: 7 weeks after placement of balloon
|
7 weeks after placement of balloon
|
Lung head ratio
Time Frame: 7 weeks after placement of balloon
|
7 weeks after placement of balloon
|
Survival at 30 days
Time Frame: 30 days post delivery
|
30 days post delivery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maternal complications
Time Frame: After Insertion of Balloon to delivery- (from 27 weeks gestational age up to 39 weeks gestational age)
|
Maternal complications include preterm labor, premature preterm rupture of membranes, oligohydramnios, polyhydramnios, and chorioamnionitis.
|
After Insertion of Balloon to delivery- (from 27 weeks gestational age up to 39 weeks gestational age)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anthony Johnson, DO, The University of Texas Health Science Center, Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2015
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
November 2, 2015
First Submitted That Met QC Criteria
November 2, 2015
First Posted (Estimated)
November 4, 2015
Study Record Updates
Last Update Posted (Actual)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 4, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-15-0796
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Diaphragmatic Hernia
-
Timothy CrombleholmeRecruitingCongenital Diaphragmatic HerniasUnited States
-
University of California, San FranciscoNo longer availableSevere Congenital Diaphragmatic HerniaUnited States
-
Martin-Luther-Universität Halle-WittenbergUnknownSevere Congenital Diaphragmatic HerniaGermany
-
University of UtahCompletedCongenital Diaphragmatic Hernia | Congenital Diaphragmatic Eventration | Congenital Hiatal Hernia | Congenital Diaphragmatic DisordersUnited States
-
Connecticut Children's Medical CenterRecruitingCongenital Diaphragmatic HerniasUnited States
-
University Hospital, Strasbourg, FranceTerminatedCongenital Diaphragmatic HerniasFrance
-
University of Sao Paulo General HospitalMinistry of Health, BrazilUnknownCongenital Diaphragmatic Hernia | Congenital AbnormalityBrazil
-
University Hospital, LilleAPEHDia, a french CDH patient association; Rare Disease Foundation, FranceNot yet recruitingCongenital Diaphragmatic Hernia
-
University of California, DavisNot yet recruitingCongenital Diaphragmatic HerniaUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruitingCongenital Diaphragmatic HerniaBelgium
Clinical Trials on FETO therapy
-
Children's Hospitals and Clinics of MinnesotaAllina Health SystemRecruiting
-
University of Sao Paulo General HospitalMinistry of Health, BrazilUnknownCongenital Diaphragmatic Hernia | Congenital AbnormalityBrazil
-
Alireza ShamshirsazNot yet recruitingCongenital Diaphragmatic HerniaUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingCongenital Diaphragmatic HerniaFrance
-
Sohag UniversityRecruitingHepatocellular Carcinoma PatientsEgypt
-
Children's Hospital Medical Center, CincinnatiRecruitingCongenital Diaphragmatic Hernia | Pulmonary Hypoplasia | Pulmonary; HypertensionUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruitingCongenital Diaphragmatic HerniaBelgium
-
University of Sao Paulo General HospitalUniversity of Sao PauloUnknown
-
Timothy CrombleholmeRecruitingCongenital Diaphragmatic HerniasUnited States
-
Connecticut Children's Medical CenterRecruitingCongenital Diaphragmatic HerniasUnited States